CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies. It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.
Investigated for use/treatment in bladder cancer.
Moffitt Cancer Center, Tampa, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University, Tampa, Florida, United States
Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.